Jan 10, 2022 / 11:00PM GMT
Operator
Before starting, I'd like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in the most recent Form 20-F and in our other SEC filings. Please also refer to the important notice on Page 2 of the presentation.
Now please let me introduce today's presenters and panel: Christophe Weber, President and CEO; Andrew Plump, President of R&D; Costa Saroukos, Chief Financial Officer; and Ramona Sequeira, President, U.S. Business Unit and Global Portfolio Commercialization.
First, Christophe will give you a presentation. And after that, we will have a question-and-answer session. Now we would like to begin.
Christophe Weber - Takeda Pharmaceutical Company Limited - President, CEO & Representative Director
Thank you very much. It's a great pleasure to be with you. I wish we could be setting the meeting rooms
Takeda Pharmaceutical Co Ltd Management Call Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers